Functioning tailor-made 3D-printed vascular graft for hemodialysis

• Published in: The journal of vascular access 2024-01, Vol.25 (1), p.244-253
• Main Authors: Li, Ming-Chia, Chang, Pu-Yuan, Luo, Huai-Rou, Chang, Ling-Yuan, Lin, Chuan-Yi, Yang, Chih-Yu, Lee, Oscar Kuang-Sheng, Wu Lee, Yan-Hwa, Tarng, Der-Cherng
• Format: Article
• Language: English
• ISSN: 1129-7298; 1724-6032
• DOI: 10.1177/11297298221086173

Background: The two ends of arteriovenous graft (AVG) are anastomosed to the upper limb vessels by surgery for hemodialysis therapy. However, the size of upper limb vessels varies to a large extent among different individuals. Methods: According to the shape and size of neck vessels quantified from the preoperative computed tomography angiographic scan, the ethylene-vinyl acetate (EVA)-based AVG was produced in H-shape by the three-dimensional (3D) printer and then sterilized. This study investigated the function of this novel 3D-printed AVG in vitro and in vivo. Results: This 3D-printed AVG can be implanted in the rabbit’s common carotid artery and common jugular vein with ease and functions in vivo. The surgical procedure was quick, and no suture was required. The blood loss was minimal, and no hematoma was noted at least 1 week after the surgery. The blood flow velocity within the implanted AVG was 14.9 ± 3.7 cm/s. Additionally, the in vitro characterization experiments demonstrated that this EVA-based biomaterial is biocompatible and possesses a superior recovery property than ePTFE after hemodialysis needle cannulation. Conclusions: Through the 3D printing technology, the EVA-based AVG can be tailor-made to fit the specific vessel size. This kind of 3D-printed AVG is functioning in vivo, and our results realize personalized vascular implants. Further large-animal studies are warranted to examine the long-term patency.